Utilization of bladder cancer RTConcurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population
Section snippets
Study design and population
This is a population-based, retrospective cohort study to describe management and outcome of muscle-invasive bladder cancer in the Canadian province of Ontario. Ontario has a population of approximately 13.5 million people and a single-payer universal health insurance program. All incident cases of bladder cancer in Ontario with urothelial carcinoma, adenocarcinoma, and squamous cell histology treated with RC or RT during 1999–2013 were included. The study population was classified into three
Study population
During 1999–2013, 1192 patients in Ontario with bladder cancer underwent curative-intent RT (Supplemental eFig. 1). As shown in Supplemental eFigs. 1 and 2, the vast majority (>75%) of patients treated with curative intent in Ontario undergo cystectomy and not radical RT. Moreover, substantially more patients with bladder cancer are treated with palliative-intent RT rather than curative-intent RT. Over the three study periods, the proportion of patients treated with radical RT and radical
Discussion
We describe the management and outcomes of all patients with bladder cancer treated with curative-intent RT in the general population of Ontario during 1999–2013. Several important findings have emerged. Second, while the proportion of patients treated with RT vs cystectomy has remained relatively stable, the proportion of those cases treated with CRT has increased significantly in the most recent years. Second, advanced age, and greater comorbidity are independently associated with decreased
Funding
Dr. Booth is supported as the Canada Research Chair in Population Cancer Care. This work was supported by grants from the Canada Foundation for Innovation and the Canadian Cancer Society Research Institute.
Conflict of interests statement
The authors have no conflict of interests to disclose.
Acknowledgments
Parts of this material are based on data and information provided by Cancer Care Ontario. However, the analysis, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of Cancer Care Ontario.
Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI.
This study was supported by the
References (30)
- et al.
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines
Eur Urol
(2014) - et al.
Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study
Clin Oncol (R Coll Radiol)
(2014) - et al.
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience
Eur Urol
(2012) - et al.
Waiting for radiotherapy in Ontario
Int J Radiat Oncol Biol Phys
(1994) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol
(1992) - et al.
Radiotherapy for bladder cancer
Urology
(2007) - et al.
Patterns of referral to radiation oncology among patients with bladder cancer: a population-based study
Clin Oncol (R Coll Radiol)
(2017) - et al.
Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study
Int J Radiat Oncol Biol Phys
(2014) - et al.
Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
J Clin Oncol
(2016) - National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management; 2015. Available at:...
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients
J Clin Oncol
Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results
J Clin Oncol
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group
J Clin Oncol
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
N Engl J Med
Cited by (11)
Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?
2021, Clinical OncologyCitation Excerpt :With strong evidence for the use of CRS, there is a lack of qualitative information to understand these patterns of prescribing, particularly for an intervention that has shown benefit without increased toxicity. The issue seems to be driven by physician preference [79,80] rather than patient-related factors alone. The introduction of operational delivery networks for radiotherapy across England should help to drive the implementation of bladder CRS as standard in the future using the available state of the art radiotherapy techniques [81].
Radiotherapy Management of Muscle Invasive Bladder Cancer: Evaluation of a National Cohort
2019, Clinical OncologyCitation Excerpt :Despite the reported acceptable tolerability and toxicity reported in the CRT trials, CRT in this non-trial population was only prescribed in just 40% of this UK cohort. A recent publication by Ghate et al. [32], detailing the penetrance of CRT between 1999 and 2013, using the Ontario Cancer Registry, describes increasing use with time, to a level of 48% of patients receiving CRT 2009–2013. This low-level uptake within the UK, despite unequivocal recommendations, reflects hesitancy in the treating clinicians and a reluctance to embrace evidence-based medicine.
Combined radiotherapy and chemotherapy
2022, NowotworyOUTCOME OF PATIENTS TREATED WITH BLADDER PRESERVATION PROTOCOL IN UROTHELIAL CARCINOMA OF URINARY BLADDER
2021, Pakistan Armed Forces Medical JournalRadiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma
2021, Translational Andrology and UrologyDown-regulation of autophagy-associated protein increased acquired radio-resistance bladder cancer cells sensitivity to taxol
2021, International Journal of Radiation Biology